AbbVie closes $200M Nimble Therapeutics acquisition
by
Contributor since / Followers
Contributor since / Followers
19 hours ago
SB
- AbbVie (NYSE:ABBV) has completed its $200M acquisition of Nimble Therapeutics.
- Nimble’s lead asset is an oral peptide IL23R inhibitor in preclinical development for psoriasis.
- Nimble was spun out of Roche (OTCQX:RHHBY) in 2019.